利用人工智能识别Bufalin作为雌激素受体α的分子降解剂
Shilong Jiang1,2, Keyi Liu3, Ting Jiang4
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Nature communications
|August 22, 2025
概括
布法林是一种天然化合物,作为分子,降低雌激素受体α (ERα). 这种机制可以逆转乳腺癌的他莫西芬耐药性,从而提供一种新的治疗策略.
科学领域:
- 药理学
- 分子生物学
- 药物发现
背景情况:
- 确定目标对于从天然产品开发新型抗癌药物至关重要.
- 布法林具有抗癌性质,但其分子机制需要阐明.
研究的目的:
- 确定Bufalin的分子点和作用机制.
- 评估Bufalin在乳腺癌中克服内分泌抵抗的潜力.
主要方法:
- 综合多预测策略包括人工智能,分子对接和分子动力学模拟.
- 生物物理验证试验 (SPR,生物拉下,热转移).
- 在体外,体内和患者衍生器官对他莫西芬耐药性的模型.
主要成果:
- 布法林直接与雌激素受体α (ERα) 结合.
- 布法林作为一个分子剂,通过STUB1介导的无化促进ERα降解.
- 在临床前模型和患者衍生器官中,布法林可逆转他莫西芬耐药性.
结论:
- 针对ERα降解的Bufalin的分子合机制为克服他莫西芬耐药性提供了一个新的策略.
- 布法林对内分泌抵抗性乳腺癌具有显著的治疗潜力.
相关概念视频
Transducer Mechanism: Nuclear Receptors
6.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.4K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Sedatives and Hypnotics Drugs: Miscellaneous Agents
939
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
939
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
682
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
682
Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K


